Cancer Research The Future of Cancer Research: Science and Patient Impact  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 58, 3905-3908, September 1, 1998]
© 1998 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zuckier, L. S.
Right arrow Articles by Morrison, S. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zuckier, L. S.
Right arrow Articles by Morrison, S. L.

Chimeric Human-Mouse IgG Antibodies with Shuffled Constant Region Exons Demonstrate that Multiple Domains Contribute to in Vivo Half-Life

Lionel S. Zuckier1, Chee J. Chang, Matthew D. Scharff and Sherie L. Morrison

Departments of Nuclear Medicine [L. S. Z.], Epidemiology and Biostatistics [C. J. C.], and Cell Biology [M. D. S.], Albert Einstein College of Medicine, Bronx, New York 10461, and Department of Microbiology and Molecular Genetics and the Molecular Biology Institute, University of California, Los Angeles, Los Angeles, California 90095 [S. L. M.]

Structural features that determine the differing rates of immunoglobulin catabolism are of great relevence to the engineering of immunologically active reagents. Sequences in the CH2 and CH3 region of IgG have been shown to regulate the rate of clearance through their interaction with FcRn. In an attempt to probe additional structural features that regulate antibody half-life, we have investigated two families of chimeric antibodies, composed of identical murine heavy and light antidansyl variable regions joined to human {kappa} light-chains and wild-type or shuffled human IgG heavy-chain constant regions. These antibodies were iodinated, and their clearance was studied in severe combined immunodeficient mice hosts by whole-body radioactivity measurements. Clearances of the wild-type and recombinant antibodies were biphasic. In a panel of immunoglobulins derived from IgG2 and IgG3, as successive domains were varied from {gamma}2 to {gamma}3, ß-phase half-life gradually decreased from 337.0 h to 70.6 h. Statistical analysis suggested that the composition of each of the three domains affected half-life, and no single region of the molecule by itself determined the rate of clearance. In the second panel of immunoglobulins derived from IgG1 and IgG4, the construct with the amino terminus portion of the molecule derived from IgG4, joined within the CH2 domain to the COOH terminus portion of IgG1, had a half-life paradoxically greater than either IgG1 or IgG4 (P < 0.012). All four IgG1/IgG4 constructs demonstrated presence of the concentration catabolism phenomenon, which is a unique hallmark of immunoglobulin catabolism. The contribution of all three constant region domains to immunoglobulin half-life may be due to distant conformational effects in addition to direct binding to protective receptors, and emphasizes the importance of distant sequences on the rate of immunoglobulin catabolism. Interesting possibilities regarding mechanisms controlling immunoglobulin metabolism are raised by the hybrid {gamma}4/{gamma}1 molecule with a half-life greater than either parental immunoglobulin. Understanding the relationships between the structure of these molecules and their clearance rate will further our ability to produce immunoglobulins with improved pharmacokinetic properties.

1 To whom requests for reprints should be addressed, at Department of Nuclear Medicine, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Ullmann Building, Room 121, Bronx, NY 10461.

Received 9/26/97. Accepted 7/ 2/98.




This article has been cited by other articles:


Home page
Cancer Res.Home page
A. Natsume, M. In, H. Takamura, T. Nakagawa, Y. Shimizu, K. Kitajima, M. Wakitani, S. Ohta, M. Satoh, K. Shitara, et al.
Engineered Antibodies of IgG1/IgG3 Mixed Isotype with Enhanced Cytotoxic Activities
Cancer Res., May 15, 2008; 68(10): 3863 - 3872.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. P. Lambert, L. Rauova, M. Bailey, M. C. Sola-Visner, M. A. Kowalska, and M. Poncz
Platelet factor 4 is a negative autocrine in vivo regulator of megakaryopoiesis: clinical and therapeutic implications
Blood, August 15, 2007; 110(4): 1153 - 1160.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
M. Firan, R. Bawdon, C. Radu, R. J. Ober, D. Eaken, F. Antohe, V. Ghetie, and E. S. Ward
The MHC class I-related receptor, FcRn, plays an essential role in the maternofetal transfer of {gamma}-globulin in humans
Int. Immunol., August 1, 2001; 13(8): 993 - 1002.
[Abstract] [Full Text] [PDF]


Home page
GlycobiologyHome page
A. Wright, Y. Sato, T. Okada, K. H. Chang, T. Endo, and S. L. Morrison
In vivo trafficking and catabolism of IgG1 antibodies with Fc associated carbohydrates of differing structure
Glycobiology, December 1, 2000; 10(12): 1347 - 1355.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1998 by the American Association for Cancer Research.